—

Fagron NV (FAGR.BR) — the peer cohort

As of 2026-10-08 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Fagron NV ranks 11 of 12 in its cohort on the Closelooknet composite (52/100) — the cohort is led by Halozyme Therapeutics Inc at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
FAGR.BR Fagron NV 52 43 56 60 info 11.9%
ROVI.MC Laboratorios Farmaceuticos ROVI 61 27 77 52 warn 31.8%
LNTH Lantheus Holdings Inc 60 68 74 57 info 10.5%
KNSA Kiniksa Pharmaceuticals Ltd 57 94 59 21 ok 5.1%
AMRX Amneal Pharmaceuticals, Inc. Class A Common Stock 54 89 58 42 ok 7.2%
GALDY GALDERMA GROUP AG 54 44 59 28 info 15%
ALM.MC Almirall S.A. 53 22 46 68 warn 27.1%
TUB.BR Tubize-Fin 26 14 19 27 warn 32.2%
HALO Halozyme Therapeutics Inc 74 94 94 51 ok 6%
BION.SW BB Biotech AG 73 57 96 81 info 16.1%
DXCM DexCom Inc 66 83 80 37 watch 9%
ANN.AU Ansell Ltd 64 94 47 53 ok 1.7%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-08

Quick answers

Who are Fagron NV's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Laboratorios Farmaceuticos ROVI (ROVI.MC), Lantheus Holdings Inc (LNTH), Kiniksa Pharmaceuticals Ltd (KNSA), Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX), GALDERMA GROUP AG (GALDY), Almirall S.A. (ALM.MC), Tubize-Fin (TUB.BR), Halozyme Therapeutics Inc (HALO) and others.

How does FAGR.BR score against its peers?

Fagron NV's composite reads 52/100, ranking 11 of 12 in its cohort as of 2026-10-08; the cohort's highest composite is Halozyme Therapeutics Inc at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.